Veröffentlichungen
Originalarbeiten, Bücher, Buchkapitel und Übersichtsartikel von Prof. Marcus Maurer
Verwendung: Beginnen Sie mit einer Übersicht über alle Publikationen. Verwenden Sie Tag-Links, um markierte Dokumente aufzulisten oder eine ganze Kategorie aufzulisten, z.B. Original Work (Originalarbeiten), Books (Bücher), Book Chapters (Buchkapitel), Reviews (Übersichtsartikel). Wenn Sie wissen, was Sie suchen, dann geben Sie diesen Begriff in das Suchfeld ein.
Treatment of acute attacks of hereditary angioedema (HAE) with the bradykinin B2 receptor antagonist icatibant
| Filename | 37. Magerl et al.,HAE B2 receptor,Rev. Port. de Imunoalerg.2010.pdf |
| Filesize | 161,74 kB |
| Version | r.037 |
| Date added | Juni 26, 2020 |
| Downloaded | 0 times |
| Category | Reviews |
| Tags | bradykinin, Hereditary Angioedema, Icatibant |
| Authors | Magerl, M., Keßler, B., and Maurer, M. |
| Citation | Magerl, M., Keßler, B., and Maurer, M.: Treatment of acute attacks of hereditary angioedema (HAE) with the bradykinin B2 receptor antagonist icatibant. Rev. Port. Imunoalergologia 2010: 18; 207-214. |
| Corresponding authors | Maurer, M. |
| DocNum | R.37 |
| DocType | |
| Edition; Page | 18; 207-214 |
| IF | N/A |
| Publisher | Rev. Port. Imunoalergologia |
| ReleaseDate | 2010 |
Icatibant is a selective and competitive bradykinin B2 receptor antagonist. It was approved in 2008, for the symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults with a deficiency of the C1 esterase inhibitor. Icatibant is the first subcutaneous treatment for HAE. The efficacy of icatibant in the treatment of moderate to very severe cutaneous and abdominal attacks in patients with HAE was investigated in two Phase III trials in comparison with tranexamic acid and with placebo, respectively. The time to onset of symptom relief, the primary end point of the trial, was significantly shortened with icatibant compared to tranexamic acid. Icatibant demonstrated a favourable safety profile in clinical trials with no drug-related serious adverse events.
(Last update: 12.2023)
| Number of original publications in peer-reviewed journals: | 580 |
| Number of reviews in peer-reviewed journals: | 210 |
| Number of publications (original work and reviews) in peer-reviewed journals: | 790 |
| Cumulative IF for original publications in peer-reviewed journals: | 4196.39 |
| Cumulative IF for reviews in peer-reviewed journals: | 1409.32 |
| Cumulative IF of publications (original work & reviews) in peer-reviewed journals: | 5605.71 |
| Total number of citations: 36,836, h-index: 99 (Web of Science December 2023) | 36836 |
Download-Information
Um die angebotenen Veröffentlichungen herunterladen zu können, müssen Sie sich einloggen. Wenn Sie das Login nicht kennen, schreiben Sie mir bitte Ihre Anfrage.